Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2024-02-15 00:00:00 ET · period of report 2024-02-13 · accession 0001714899-24-000061 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-15 | 2024-02-13 | DNLI | Watts Ryan J. | Pres, CEO, Dir | S - Sale | $17.29 | -9,589 | 238.1K | -4% | -$165.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-13 | S | D | 9,589 | $17.29 | 238,067 | D | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price (F3) Includes 202,200 RSUs. (F4) Reflects 25,759 shares previously disclosed as held indirectly; but have been determined to be held directly. |